Digital Health
Technology revolutionizing health care
Digital health solutions are transforming the health care landscape. Our investment teams use propriety research and industry expertise to find opportunities in one of the fastest-growing segments in health care.
Why invest in digital health?
Digitalization is revolutionizing the health care sector.
With research and development contributing to breakthroughs that would previously have been unimaginable, it has the potential to markedly improve the quality of medical services and curb rising costs.
Digital health is one of the fastest growing segments in health care, opening up attractive prospects for investors with long-term investment horizons.
Digitalization as a growth driver
The medical world is far from immune to the effects of the digital revolution; indeed, the health care sector offers particularly fertile ground for the methods and tools used in digitalization. Many areas of research in medicine today, such as genetic sequencing and the genetic analysis of entire population groups, feature an extremely high density of data.
Support from systems that make use of artificial intelligence (AI) can considerably speed up this type of work. Digitalization also allows existing processes to be applied in a way that is not only more precise, but also faster and entails fewer side effects – a prime example being robots in operating theaters. Furthermore, with factors such as the increasing complexity of modern medicine and demographic changes (for example the aging population) driving health care costs upward at an alarming rate, digitalization can also help by improving efficiency through the optimization of digital processes. This constellation makes digital health a real growth market.
Our digital health investment fund
The Credit Suisse (Lux) Digital Health Equity Fund offers investors the opportunity to invest in three subthemes: research and development, treatments, and efficiency. The fund focuses on pure-play1 companies that have developed innovative technology applications capable of fundamentally changing the health care system, lowering the cost of health care, and/or improving patient outcomes. The portfolio typically consists of 40 to 60 stocks selected through bottom-up fundamental analysis.2
The fund applies exclusions and integrates ESG3 considerations into the investment process in line with the principles of the Credit Suisse Sustainable Investment Framework.
Risks
- Investors may lose part or all of the invested capital.
- Equity markets can be volatile, especially in the short term.
- A slowdown in global economic growth could have a negative impact on portfolio companies and equity markets in general.
- Political developments in the health care sector may have an adverse impact on the fund’s performance.
- Portfolio companies are exposed to competition risk associated with the threat that a better technology or a more innovative solution will be launched on the market.
- Exposure to small- and mid-cap securities may result in higher volatility and may result in increased liquidity risk.
- Exposure to early-stage and highly innovative companies may result in significantly higher volatility.
- In the case of significant inflows or outflows, a disparity in the value date of stocks from different countries may result in unintended short-term currency exposures.
Investment possibilities
Find investment products that suit your personal needs. Choose from our extensive range of investment solutions across all major asset classes, and access all product-related information.
You can also follow a fund and receive the monthly factsheet quickly and easily.
Get in touch with Asset Management
Contact us to learn about exciting investment opportunities. We are here to help you achieve your investment goals.
The full offering documentation including complete information on risks may be obtained free of charge from a Credit Suisse client advisor, representative, or, where applicable, via Fundsearch (credit-suisse.com/fundsearch).
1 We define a pure player as a company in which at least 50% of revenue comes from the digital health theme.
2 An investment approach that focuses on the analysis of individual stocks and de-emphasizes the macroeconomic environment.
3 ESG stands for environmental (E), social (S), and governance (G). For further information about the ESG investment criteria and the sustainability-related aspects of the fund, please consider the legal and regulatory documents of the fund (e.g. the prospectus) and visit credit-suisse.com/esg. In addition to sustainability-related aspects, the decision to invest in the fund should take into account all objectives and characteristics of the fund as described in its prospectus or in the information which is to be disclosed to investors in accordance with applicable regulations.
Singapore: This content may only be distributed to persons in Singapore who are "institutional investors" or "accredited investors" as defined under the Securities and Futures Act 2001. Listed on CISNet as a restricted collective investment scheme.
This is a marketing communication.
To the extent that these materials contain statements about the future, such statements are forward looking and are subject to a number of risks and uncertainties and are not a guarantee of future results/performance.
The individuals mentioned above only conduct regulated activities in the jurisdiction(s) where they are properly licensed, where relevant.
Source: Credit Suisse, unless otherwise specified.
Unless noted otherwise, all illustrations in this document were produced by Credit Suisse AG and/or its affiliates with the greatest of care and to the best of its knowledge and belief.
This material constitutes marketing material of Credit Suisse AG and/or its affiliates (hereafter "CS").
This material does not constitute or form part of an offer or invitation to issue or sell, or of a solicitation of an offer to subscribe or buy, any securities or other financial instruments, or enter into any other financial transaction, nor does it constitute an inducement or incitement to participate in any product, offering or investment. This marketing material is not a contractually binding document or an information document required by any legislative provision. Nothing in this material constitutes investment research or investment advice and may not be relied upon. It is not tailored to your individual circumstances, or otherwise constitutes a personal recommendation, and is not sufficient to take an investment decision. The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to be reliable. CS provides no guarantee with regard to the content and completeness of the information and where legally possible does not accept any liability for losses that might arise from making use of the information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient. The information provided in this material may change after the date of this material without notice and CS has no obligation to update the information. This material may contain information that is licensed and/or protected under intellectual property rights of the licensors and property right holders. Nothing in this material shall be construed to impose any liability on the licensors or property right holders. Unauthorised copying of the information of the licensors or property right holders is strictly prohibited. The full offering documentation including, the prospectus or offering memorandum, the Key Investor Information Document (KIID), the Key Information Document (KID), the fund rules, as well as the annual and bi-annual reports ("Full offering documentation"), as the case may be, may be obtained free of charge in one of the languages listed below from the legal entity/entities indicated below and where available via Fundsearch (credit-suisse.com/fundsearch). Information on your local distributors, representatives, information agent, paying agent, if any, and your local contacts in respect of the investment product(s) can be found below. The only legally binding terms of any investment product described in this material, including risk considerations, objectives, charges and expenses are set forth in the prospectus, offering memorandum, subscription documents, fund contract and/or any other fund governing documents. For a full description of the features of the products mentioned in this material as well as a full description of the opportunities, risks, and costs associated with the respective products, please refer to the relevant underlying securities prospectuses, sales prospectuses, or other additional product documents, which we will be pleased to provide to you at any time upon request. The investment promoted in this marketing material concerns the acquisition of units or shares in a fund and not of any underlying assets. The underlying assets are owned by the fund only. This material may not be forwarded or distributed to any other person and may not be reproduced. Any forwarding, distribution or reproduction is unauthorized and may result in a violation of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The securities referred to herein have not been, and will not be, registered under the Securities Act, or the securities laws of any states of the United States and, subject to certain exceptions, the securities may not be offered, pledged, sold or otherwise transferred within the United States or to, or for the benefit or account of, U.S. persons. In addition, there may be conflicts of interest with regards to the investment. In connection with the provision of services, Credit Suisse AG and/or its affiliates may pay third parties or receive from third parties, as part of their fee or otherwise, a one-time or recurring fee (e.g., issuing commissions, placement commissions or trailer fees). Prospective investors should independently and carefully assess (with their tax, legal and financial advisers) the specific risks described in available materials, and applicable legal, regulatory, credit, tax and accounting consequences prior to making any investment decision. The alternative investment fund manager or the (UCITS) management company, as applicable, may decide to terminate local arrangements for the marketing of the shares/units of a fund, including terminating registrations or notifications with the local supervisory authority. A summary of investor rights for investing into European Economic Area domiciled investment funds managed or sponsored by Credit Suisse Asset Management can be obtained in English via www.credit-suisse.com/am/regulatory-information, local laws relating to investor rights may apply.
For Persons in Singapore: This document forms part of, and should be read and considered in the context of and in conjunction with the offer document of the product(s) named in this document (“Product”). This document together with the offer document, forms the information memorandum relating to the offer of the securities/shares/interests/units in or of the Product (“Information Memorandum”). The Product is not authorised under section 286 of the Securities and Futures Act 2001 (“SFA”) or recognised under section 287 of the SFA by the Monetary Authority of Singapore (“MAS”) and its securities/shares/interests/units are not allowed to be offered to the retail public in Singapore. Each of the Information Memorandum (including this document and the offer document) and any other document or material (in any medium) issued in connection with the offer or sale of the securities/shares/interests/units in or of the Product is not a prospectus as defined in the SFA, and has not been and will not be lodged or registered as a prospectus with the MAS. Accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply. A potential investor should consider carefully whether the investment is suitable for him/her/it. This document and any other document or material (in any medium) issued in connection with the offer or sale of the securities/shares/interests/units in or of the Product may not be circulated or distributed, and the securities/shares/interests or units in or of the Product may not be offered or sold, whether directly or indirectly, to any person in Singapore other than (a) to an institutional investor (as defined in section 4A of the SFA) in reliance on the exemption under section 304 of the SFA; (b) to a “relevant person” as defined in section 305(5) of the SFA; or (c) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. This document has been prepared and issued for distribution in Singapore to institutional investors and accredited investors (each as defined in the SFA). By virtue of your status as an institutional investor or accredited investor, Credit Suisse AG, Singapore Branch and Credit Suisse (Singapore) Limited (each a “CS SG Entity”) are exempted from complying with certain compliance requirements under the Financial Advisers Act 2001 (the “FAA”), the Financial Advisers Regulations (“FAR”) and the relevant notices and guidelines issued thereunder, in respect of any financial advisory service which a CS SG Entity may provide to you. These include exemptions from complying with:
(i) Section 25 of the FAA (pursuant to Regulation 33(1) of the FAR);
(ii) Section 27 of the FAA (pursuant to Regulation 34(1) of the FAR); and
(iii) Section 36 of the FAA (pursuant to Regulation 35(1) of the FAR)
Copyright © 2023 CREDIT SUISSE. All rights reserved.
For General Public only
Source: Credit Suisse, unless otherwise specified.
Unless noted otherwise, all illustrations in this document were produced by Credit Suisse AG and/or its affiliates with the greatest of care and to the best of its knowledge and belief.
This material constitutes marketing material of Credit Suisse AG and/or its affiliates (hereafter "CS"). This material does not constitute or form part of an offer or invitation to issue or sell, or of a solicitation of an offer to subscribe or buy, any securities or other financial instruments, or enter into any other financial transaction, nor does it constitute an inducement or incitement to participate in any product, offering or investment. This marketing material is not a contractually binding document or an information document required by any legislative provision. Nothing in this material constitutes investment research or investment advice and may not be relied upon. It is not tailored to your individual circumstances, or otherwise constitutes a personal recommendation, and is not sufficient to take an investment decision. The information and views expressed herein are those of CS at the time of writing and are subject to change at any time without notice. They are derived from sources believed to be reliable. CS provides no guarantee with regard to the content and completeness of the information and where legally possible does not accept any liability for losses that might arise from making use of the information. If nothing is indicated to the contrary, all figures are unaudited. The information provided herein is for the exclusive use of the recipient. The information provided in this material may change after the date of this material without notice and CS has no obligation to update the information. This material may contain information that is licensed and/or protected under intellectual property rights of the licensors and property right holders. Nothing in this material shall be construed to impose any liability on the licensors or property right holders. Unauthorised copying of the information of the licensors or property right holders is strictly prohibited. This material may not be forwarded or distributed to any other person and may not be reproduced. Any forwarding, distribution or reproduction is unauthorized and may result in a violation of the U.S. Securities Act of 1933, as amended (the “Securities Act”). In addition, there may be conflicts of interest with regards to the investment. In connection with the provision of services, Credit Suisse AG and/or its affiliates may pay third parties or receive from third parties, as part of their fee or otherwise, a one-time or recurring fee (e.g., issuing commissions, placement commissions or trailer fees). Prospective investors should independently and carefully assess (with their tax, legal and financial advisers) the specific risks described in available materials, and applicable legal, regulatory, credit, tax and accounting consequences prior to making any investment decision.
Copyright © 2023 CREDIT SUISSE. All rights reserved.
Distributor AM: Credit Suisse (Singapore) Limited, 1 Raffles Link #03/#04-01 South Lobby Singapore, 039393 Singapore I Language version available: English I Singapore - Monetary Authority of Singapore (MAS)
Distributor PB: Credit Suisse AG, Singapore Branch, 1 Raffles Link #03-01 One Raffles Link Singapore, 039393 Singapore I Language version available: English I Singapore - Monetary Authority of Singapore (MAS)
This advertisement has not been reviewed by the Monetary Authority of Singapore.